CanBreed Secures CRISPR-Cas9 Patent License to Improve Cannabis Varieties for Medical Uses

CanBreed is pleased to announce that it has executed a nonexclusive intellectual property licensing agreement for foundational CRISPR-Cas9 patents. CanBreed intends to apply gene editing tools to provide cannabis-based industries with improved raw materials for medical products.

CanBreed is confident that the integration of CRISPR technology into its breeding program, combined with its unique transformation technology, will significantly accelerate its efforts to supply farmers with cannabis varieties endowed with improved, economically critical agronomic traits.

Corteva Agriscience and the Broad Institute of MIT and Harvard have extended the license as part of their nonexclusive open licensing framework. Consistent with compliance and stewardship requirements established by the organizations, the technology must be used in accordance with all applicable international, federal, and state laws and will not be used to enhance Tetrahydrocannabinol (THC), the chemical responsible for most of the psychotropic effects of cannabis. All research, development, and commercial activities related to the license will be conducted by CanBreed, and not Corteva or the Broad.

About CanBreed: Founded in 2017, CanBreed’s goal is to increase the profitability of cannabis farming, while enabling farmers to supply uniform-quality raw material to cannabis-based industries. The company is based in Israel, where the use of cannabis is legally permissible, operating an R&D center and a seed trials and production facility there. CanBreed is managed and staffed by a multidisciplinary team of dedicated seed and genetics professionals.

© Copyright 2021 CanBreed Ltd.  - All Rights Reserved

Mobirise web creator - More here